StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) shareholders

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
63.3%
287M of 453M shares
Institutional holders
292
45 new, 35 sold out
Net institutional buying
18M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.33,366,5877.50%13G (passive) amendmentJun 30, 2026
Wayne P. Rothbaum
Joint filing with Quogue Capital LLC (11.60%)
30,000,00011.60%13D (active) amendmentFeb 20, 2024
Perceptive Advisors LLC
Joint filing with Joseph Edelman (7.30%), Perceptive Life Sciences Master Fund, Ltd. (7.30%)
22,112,2667.30%13G (passive) amendmentDec 31, 2024
Mark H. Rachesky, M.D
Joint filing with Mhr Advisors LLC (7.80%), Mhrc LLC (7.80%) and 3 more
20,083,9517.80%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of IOVAValueChange% of portfolio
BlackRock, Inc.36,957,6818.16%$153.74M+5,877,1760.00%
Mhr Fund Management LLC28,967,1036.39%$120.50M–6.28%
State Street Corp24,478,2685.40%$101.83M+7,030,1600.00%
Two Sigma Investments, LP19,010,6974.20%$79.08M+5,323,2640.06%
Vanguard Capital Management LLC18,204,2484.02%$75.73M+1,586,5110.00%
Vanguard Portfolio Management LLC14,388,9993.18%$59.86M+2,688,1550.00%
Geode Capital Management, LLC10,324,8262.28%$42.96M+1,752,2280.00%
Millennium Management LLC8,525,9191.88%$35.47M−888,3730.01%
Dimensional Fund Advisors LP6,460,4491.43%$26.88M+3,814,7470.00%
Palo Alto Investors LP5,296,2091.17%$22.03M−1,053,3543.04%
Goldman Sachs Group Inc5,096,3341.13%$21.20M−3,663,7260.00%
Nuveen, LLC4,997,1121.10%$20.79M+1,332,8340.00%
Bank Of America Corp /De/4,993,5841.10%$20.77M−3,496,5350.00%
Morgan Stanley4,986,4611.10%$20.74M−1,214,8210.00%
Jupiter Asset Management Ltd4,535,0801.00%$18.87MNew0.09%
Jane Street Group, LLC4,393,8530.97%$18.28M+219,9670.00%
Northern Trust Corp4,154,2000.92%$17.28M+1,278,6740.00%
Aqr Capital Management LLC3,869,5840.85%$16.10M+3,245,4160.01%
Wells Fargo & Company/Mn3,246,5370.72%$13.51M+1,175,0130.00%
Charles Schwab Investment Management Inc3,219,6560.71%$13.39M+435,9260.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026292287M63.3%45 / 13265 / 3553M35M
Q1 2026286269M59.4%64 / 12258 / 3873M38M
Q4 2025263262M57.8%51 / 10463 / 3661M13M
Q3 2025253214M47.3%41 / 8377 / 4027M36M
Q2 2025255223M49.2%40 / 9372 / 8450M68M
Q1 2025302240M53.0%57 / 10193 / 5439M39M
Q4 2024301242M53.3%57 / 10186 / 3628M22M
Q3 2024286237M52.4%40 / 10784 / 4652M29M
Q2 2024295236M52.1%67 / 11481 / 4139M28M
Q1 2024273227M50.1%70 / 9182 / 3348M35M
Q4 2023236214M47.2%48 / 8770 / 3627M26M
Q3 2023227214M47.1%41 / 10752 / 3145M31M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

185 funds held IOVA in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of IOVAValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF14,493,8123.20%$60.29M0.56%Jun 30, 2026
Vanguard Total Stock Market Index Fund13,485,6792.98%$56.10M0.00%Jun 30, 2026
iShares Russell 2000 ETF10,352,9182.29%$43.07M0.05%Jun 30, 2026
Vanguard Small-Cap Index Fund4,858,2311.07%$20.21M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund4,351,3280.96%$17.71M0.05%Jul 31, 2026
Vanguard Extended Market Index Fund4,305,0780.95%$17.91M0.02%Jun 30, 2026
iShares Russell 2000 Value ETF3,723,2940.82%$15.49M0.11%Jun 30, 2026
Vanguard Small-Cap Value Index Fund3,081,1660.68%$12.82M0.02%Jun 30, 2026
iShares Biotechnology ETF2,737,3760.60%$11.39M0.13%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund2,707,9900.60%$11.02M0.27%Jul 31, 2026
Vanguard Strategic Equity Fund2,018,6060.45%$8.40M0.07%Jun 30, 2026
Vanguard Russell 2000 Index Fund1,733,8130.38%$7.11M0.04%May 31, 2026
Fidelity Extended Market Index Fund1,727,8750.38%$7.08M0.02%May 31, 2026
Schwab U.S. Small-Cap ETF1,615,5340.36%$6.62M0.03%May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1,439,8420.32%$5.99M0.05%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Frederick G. VogtInterim CEO & General Counsel, Director604,1440.13%Nov 13, 2026
Daniel Gordon KirbyChief Commercial Officer160,5760.04%Nov 12, 2026
Corleen M. RocheChief Financial Officer35,9460.01%Nov 10, 2026
Noah BerkowitzChief Medical Officer––Oct 2, 2026
Raj K. PuriChief Regulatory Officer260,8420.06%Sep 10, 2026
Igor BilinskyChief Operating Officer142,0740.03%Sep 10, 2026
Finckenstein Friedrich GrafChief Medical Officer144,0870.03%Jun 9, 2026
Matthew W. RosinackSVP, Finance (Int. PFO & PAO)89,1290.02%Jul 10, 2025
Jean-Marc BelleminChief Financial Officer64,9930.01%Jun 4, 2025
Michael WeiserDirector133,3030.03%Jun 18, 2026
Iain D. DukesDirector54,0000.01%Jun 18, 2026
Ryan D. MaynardDirector57,5000.01%Jun 18, 2026
Athena CountouriotisDirector––Jun 18, 2026
Wendy L. YarnoDirector––Jun 17, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Frederick G. Vogt
Interim CEO & General Counsel, Director
Nov 11, 2026Tax withholding−191,303$8.09$1.55M604,144
Frederick G. Vogt
Interim CEO & General Counsel, Director
Nov 11, 2026Option exercise+200,000$7.55$1.51M795,447
Daniel Gordon Kirby
Chief Commercial Officer
Nov 10, 2026Tax withholding−3,935$8.08$31.79K160,576
Daniel Gordon Kirby
Chief Commercial Officer
Nov 10, 2026Option exercise+10,000––164,511
Corleen M. Roche
Chief Financial Officer
Nov 6, 2026Tax withholding−5,311$8.04$42.70K35,946
Corleen M. Roche
Chief Financial Officer
Nov 6, 2026Option exercise+12,500––41,257
Raj K. Puri
Chief Regulatory Officer
Sep 8, 2026Option exercise+9,766––260,842
Raj K. Puri
Chief Regulatory Officer
Sep 8, 2026Tax withholding−4,478$8.70$38.96K256,364
Igor Bilinsky
Chief Operating Officer
Sep 8, 2026Tax withholding−3,976$8.70$34.59K142,074
Igor Bilinsky
Chief Operating Officer
Sep 8, 2026Option exercise+7,813––146,050
Frederick G. Vogt
Interim CEO & General Counsel, Director
Sep 8, 2026Tax withholding−6,638$8.70$57.75K595,447
Frederick G. Vogt
Interim CEO & General Counsel, Director
Sep 8, 2026Option exercise+15,626––602,085
Igor Bilinsky
Chief Operating Officer
Sep 1, 2026Tax withholding−4,472$8.28$37.03K138,237
Igor Bilinsky
Chief Operating Officer
Sep 1, 2026Option exercise+8,789––142,709
Raj K. Puri
Chief Regulatory Officer
Sep 1, 2026Tax withholding−2,508$8.28$20.77K251,076
Raj K. Puri
Chief Regulatory Officer
Sep 1, 2026Option exercise+5,470––253,584
Frederick G. Vogt
Interim CEO & General Counsel, Director
Sep 1, 2026Tax withholding−17,702$8.28$146.57K586,459
Frederick G. Vogt
Interim CEO & General Counsel, Director
Sep 1, 2026Option exercise+41,669––604,161
Daniel Gordon Kirby
Chief Commercial Officer
Aug 10, 2026Tax withholding−2,436$6.40$15.59K154,511
Daniel Gordon Kirby
Chief Commercial Officer
Aug 10, 2026Option exercise+10,001––156,947
Corleen M. Roche
Chief Financial Officer
Aug 6, 2026Option exercise+49,995––49,995
Corleen M. Roche
Chief Financial Officer
Aug 6, 2026Tax withholding−21,238$6.21$131.89K28,757
Frederick G. Vogt
Interim CEO & General Counsel, Director
Jun 5, 2026Tax withholding−6,638$4.23$28.08K562,492
Frederick G. Vogt
Interim CEO & General Counsel, Director
Jun 5, 2026Option exercise+15,625––569,130
Finckenstein Friedrich Graf
Chief Medical Officer
Jun 5, 2026Option exercise+7,813––144,087
Finckenstein Friedrich Graf
Chief Medical Officer
Jun 5, 2026Tax withholding−3,976$4.23$16.82K140,111
Igor Bilinsky
Chief Operating Officer
Jun 5, 2026Option exercise+7,813––137,896
Igor Bilinsky
Chief Operating Officer
Jun 5, 2026Tax withholding−3,976$4.23$16.82K133,920
Raj K. Puri
Chief Regulatory Officer
Jun 5, 2026Tax withholding−3,843$4.23$16.26K248,114
Raj K. Puri
Chief Regulatory Officer
Jun 5, 2026Option exercise+9,766––251,957
Raj K. Puri
Chief Regulatory Officer
Jun 1, 2026Tax withholding−2,508$3.96$9.93K242,191
Raj K. Puri
Chief Regulatory Officer
Jun 1, 2026Option exercise+5,469––244,699
Igor Bilinsky
Chief Operating Officer
Jun 1, 2026Option exercise+8,790––134,556
Igor Bilinsky
Chief Operating Officer
Jun 1, 2026Tax withholding−4,473$3.96$17.71K130,083
Frederick G. Vogt
Interim CEO & General Counsel, Director
Jun 1, 2026Option exercise+41,668––571,206
Frederick G. Vogt
Interim CEO & General Counsel, Director
Jun 1, 2026Tax withholding−17,701$3.96$70.10K553,505
Finckenstein Friedrich Graf
Chief Medical Officer
Jun 1, 2026Tax withholding−4,473$3.96$17.71K136,274
Finckenstein Friedrich Graf
Chief Medical Officer
Jun 1, 2026Option exercise+8,790––140,747
Daniel Gordon Kirby
Chief Commercial Officer
May 11, 2026Tax withholding−2,435$3.70$9.01K146,946
Daniel Gordon Kirby
Chief Commercial Officer
May 11, 2026Option exercise+10,000––149,381
Raj K. Puri
Chief Regulatory Officer
Mar 5, 2026Tax withholding−18,360$4.58$84.09K239,230
Raj K. Puri
Chief Regulatory Officer
Mar 5, 2026Option exercise+39,059––257,590
Frederick G. Vogt
Interim CEO & General Counsel, Director
Mar 5, 2026Tax withholding−26,755$4.58$122.54K529,538
Frederick G. Vogt
Interim CEO & General Counsel, Director
Mar 5, 2026Option exercise+62,493––556,293
Igor Bilinsky
Chief Operating Officer
Mar 5, 2026Tax withholding−16,628$4.58$76.16K125,766
Igor Bilinsky
Chief Operating Officer
Mar 5, 2026Option exercise+31,246––142,394
Finckenstein Friedrich Graf
Chief Medical Officer
Mar 5, 2026Tax withholding−16,520$4.58$75.66K131,957
Finckenstein Friedrich Graf
Chief Medical Officer
Mar 5, 2026Option exercise+31,246––148,477
Igor Bilinsky
Chief Operating Officer
Mar 2, 2026Tax withholding−6,903$3.79$26.16K111,148
Igor Bilinsky
Chief Operating Officer
Mar 2, 2026Option exercise+12,307––118,051
Finckenstein Friedrich Graf
Chief Medical Officer
Mar 2, 2026Option exercise+12,697––124,353
Finckenstein Friedrich Graf
Chief Medical Officer
Mar 2, 2026Tax withholding−7,122$3.79$26.99K117,231
Raj K. Puri
Chief Regulatory Officer
Mar 2, 2026Tax withholding−2,798$3.79$10.60K218,531
Raj K. Puri
Chief Regulatory Officer
Mar 2, 2026Option exercise+5,470––221,329
Frederick G. Vogt
Interim CEO & General Counsel, Director
Mar 2, 2026Tax withholding−22,809$3.79$86.45K493,800
Frederick G. Vogt
Interim CEO & General Counsel, Director
Mar 2, 2026Option exercise+52,087––516,609
Daniel Gordon Kirby
Chief Commercial Officer
Feb 24, 2026Tax withholding−34,165$3.78$129.14K139,381
Daniel Gordon Kirby
Chief Commercial Officer
Feb 24, 2026Option exercise+120,000––173,546
Daniel Gordon Kirby
Chief Commercial Officer
Feb 10, 2026Tax withholding−16,450$2.60$42.77K53,546
Daniel Gordon Kirby
Chief Commercial Officer
Feb 10, 2026Option exercise+39,996––69,996

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
14.45%
65M shares short
Days to cover
4.2
At 16M shares a day
Change since last report
+10.6%
From 59M shares
Short volume, 20 days
38.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Iovance Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 575,562 shares on Oct 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Ryan D. Maynard
Director
Nov 12, 202450,000$503.10KNov 12, 2024Stock Option (right to buy)

See a number that looks wrong?